US FDA’s ARIA Analysis Adds Earlier Scan To Biogen/Eisai Leqembi Label

 
• By Bridget Silverman
  
The US FDA added a fourth MRI scan to labeling for Biogen/Eisai's Leqembi to help identify patients with ARIA-E adverse events early. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Safety

More from United States